An 18-year-old male with a history of Charcot-Marie-Tooth disease (CMT) presented with metastatic Ewing sarcoma to the lungs. He had been followed by several healthcare professionals who ascribed his enlarging 23 cm gluteal mass to his CMT. The patient experienced a significant delay in diagnosis, not uncommon in sarcoma. This case explores the various system and cognitive errors that contributed to this delay.
Get full access to this article
View all access options for this article.
References
1.
BleyerA, O'LearyM, BarrR, RiesLAG (Eds). Cancer epidemiology in older adolescents and young adults 15–29 years of age, including SEER incidence and survival, 1975–2000 (NIH Pub. No 06-5767). Bethesda, MD: National Cancer Institute; 2006.
2.
ChauvenetAR, ShashiV, SelskyC, et al.Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol., 2003; 25(4):316–20.
3.
Trobaugh-LotrarioAD, SmithAA, OdomLF. Vincristine neurotoxicity in the presence of hereditary neuropathy. Med Pediatr Oncol., 2003; 40(1):39–43.
4.
NakamuraT, HashiguchiA, SuzukiS, et al.Vincristine exacerbates asymptomatic Charcot-Marie-Tooth disease with a novel EGR2 mutation. Neurogenetics., 2012; 13(1):77–82.
5.
NishikawaT, KawakamiK, KumamotoT, et al.Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. J Pediatr Hematol Oncol., 2008; 30(7):519–21.
6.
GrierHE, KrailoMD, TarbellNJ, et al.Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med., 2003; 348(8):694–701.
7.
GuptaAA, PappoA, SaundersN, et al.Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer., 2010; 116(13):3189–94.
8.
JedlickaP. Ewing sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol., 2010; 3(4):338–47.
9.
WidheB, WidheT. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am., 2000; 82(5):667–74.
10.
SneppenO, HansenLM. Presenting symptoms and treatment delay in osteosarcoma and Ewing's sarcoma. Acta Radiol Oncol., 1984; 23(2–3):159–62.
11.
GebhardtMC. Bone tumors in children. Differential characteristics and treatment. Postgrad Med., 1984; 76(4):87–96.
12.
PanicekDM, GoSD, HealeyJH, et al.Soft-tissue sarcoma involving bone or neurovascular structures: MR imaging prognostic factors. Radiology., 1997; 205(3):871–5.
13.
MeyerJS, NadelHR, MarinaN, et al.Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer., 2008; 51(2):163–70.
14.
BacciG, FerrariS, BertoniF, et al.Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the Istituto Rizzoli. J Clin Oncol., 2000; 18(4):885–92.
15.
CraftA, CotterillS, MalcolmA, et al.Ifosfamide-containing chemotherapy in Ewing's sarcoma: the Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol., 1998; 16(11):3628–33.
16.
CotterillSJ, AhrensS, PaulussenM, et al.Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol., 2000; 18(17):3108–14.
17.
GranowetterL, WomerR, DevidasM, et al.Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol., 2009; 27(15):2536–41.
18.
SkreH. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet., 1974; 6(2):98–118.
ZüchnerS. Charcot-Marie-Tooth neuropathy type 2A. In: PagonRA, AdamMP, BirdTD, et al. (Eds). GeneReviews [internet]. Seattle, WA: University of Washington; initial posting February18, 2005; last update August1, 2013. Accessed July29, 2013 from: www.ncbi.nlm.nih.gov/books/NBK1511
21.
NeumannY, TorenA, RechaviG, et al.Vincristine treatment triggering expression of asymptomatic Charcot-Marie-Tooth disease. Med Pediatr Oncol., 1996; 26(4):280–3.
22.
IgarashiM, ThompsonEI, RiveraGK. Vincristine neuropathy in type I and type II Charcot-Marie-Tooth disease (hereditary motor sensory neuropathy). Med Pediatr Oncol., 1995; 25(2):113–6.
23.
GraberM, GordonR, FranklinN. Reducing diagnostic errors in medicine: what's the goal?. Acad Med., 2002; 77(10):981–92.
24.
CroskerryP. The importance of cognitive errors in diagnosis and strategies to minimize them. Acad Med., 2003; 78(8):775–80.
25.
WardropD. Ockham's razor: sharpen or re-sheathe?. J R Soc Med., 2008; 101(2):50–1.
